1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Oral Fabry Drug Clears CHMP, Amicus Sets Up 'Searchable Mutation' Website

 
• By Sukaina Virji

Amicus Therapeutics Inc., which is having a roller coaster ride with its oral Fabry disease treatment, is now in touching distance of getting the drug approved in Europe. The EMA's advisory committee, CHMP, gave migalastat (Galafold) a positive recommendation on April 1, 2016 for the treatment of Fabry disease in all patients who have amenable genetic mutations.

Amicus Therapeutics Inc., which is having a roller coaster ride with its oral Fabry disease treatment, is now in touching distance of getting the drug approved in Europe. The EMA's advisory committee, CHMP, gave migalastat (Galafold) a positive recommendation on April 1, 2016 for the treatment of Fabry disease in all patients who have amenable genetic mutations.

Amicus said a final decision was expected during

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.